Population Pharmacokinetic–Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats
Authors:
- 26 November 2016
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 42 (4) , 707-718
Abstract
Background and Objectives Myelosuppression is a dose-limiting toxicity of 5-fluorouracil (5-FU). Predicting the inter- and intra-patient variability in pharmacokinetics and toxicities of 5-FU may contribute to the individualized medicine. This study aimed to establish a population pharmacokinetic–pharmacodynamic model that could evaluate the inter- and intra-individual variability in the plasma 5-FU concentration, 5-FU-induced body weight loss and myelosuppression in rats. Method Plasma 5-FU concentrations, body weight loss, and blood cell counts in rats following the intravenous administration of various doses of 5-FU for 4 days were used to develop the population pharmacokinetic–pharmacodynamic model. Results The population pharmacokinetic model consisting of a two-compartment model with Michaelis–Menten elimination kinetics successfully characterized the individual and population predictions of the plasma concentration of 5-FU and provided credible parameter estimates. The estimates of inter-individual variability in maximal rate of saturable metabolism and residual variability were 8.1 and 22.0%, respectively. The population pharmacokinetic–pharmacodynamic model adequately described the individual complete time-course of alterations in body weight loss, erythrocyte, leukocyte, and lymphocyte counts in rats treated with various doses of 5-FU. The inter-individual variability of the drug effects in the pharmacodynamic model for body weight loss was 82.6%, which was relatively high. The results of the present study suggest that not only individual fluctuations in the 5-FU concentration but also the cell sensitivity would affect the onset and degree of 5-FU-induced toxicity. Conclusion This population pharmacokinetic–pharmacodynamic model could evaluate the inter- and intra-individual variability in drug-induced toxicity and guide the assessments of novel anticancer agents in drug development.Keywords
Funding Information
- Grant-in-Aid for Scientific Research (C) from MEXT (Ministry of Education, Culture, Sports, Science and Technology) of Japan (24590223)
- Grant-in-Aid for Young Scientists (B) from MEXT (Ministry of Education, Culture, Sports, Science and Technology) of Japan (15K18937)
This publication has 41 references indexed in Scilit:
- Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase InhibitorPharmaceutical Research, 2013
- Pharmacokinetic/Pharmacodynamic Modeling of 5-Fluorouracil by Using a Biomarker to Predict Tumor Growth in a Rat Model of Colorectal CancerJournal of Pharmaceutical Sciences, 2013
- Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki RatsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- LC‐MS/MS method for simultaneous analysis of uracil, 5,6‐dihydrouracil, 5‐fluorouracil and 5‐fluoro‐5,6‐dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patientsBiomedical Chromatography, 2012
- Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapyAdvanced Drug Delivery Reviews, 2009
- Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatinBritish Journal of Clinical Pharmacology, 2008
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Pharmacokinetic variability of anticancer agentsNature Reviews Cancer, 2005
- Nonlinear Pharmacokinetics of 5-Fluorouracil in RatsJournal of Pharmaceutical Sciences, 1997